Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

AEHR Test Systems Reports 33% Revenue Growth

Aehr Test Systems said fiscal fourth-quarter revenue rose to $18.8 million from $14.1 million a year earlier, a gain of 33%. For the full fiscal year, revenue fell to $50.0 million from $59.0 million, a decline of 15%.

The company swung to a fiscal fourth-quarter profit of $1.4 million, or $0.04 a share, from a loss of $2.9 million, or $0.10 a share, in the same quarter last year. On a non-GAAP basis, fourth-quarter net income was $3.6 million, or $0.11 a share, versus a loss of $0.2 million, or $0.01 a share, a year ago.

Bookings hit a quarterly record of $60.7 million. Backlog stood at $80.6 million at May 29, 2026, and effective backlog, including bookings after quarter-end, reached $100.6 million. Cash, cash equivalents and restricted cash climbed to $116.5 million from $37.1 million at the end of the prior quarter.

For the full year, Aehr reported a net loss of $7.1 million, compared with a loss of $3.9 million the year before. Non-GAAP net income fell to $0.9 million from $4.6 million. Cash used in operating activities was $3.3 million.

Looking ahead, Aehr projected fiscal 2027 revenue of $130 million to $150 million, up from $50.0 million in fiscal 2026. That implies growth of roughly 160% to 200%. The company said the forecasted range is supported by its $100.6 million effective backlog and expected customer demand. Following these announcements, the company's shares moved 33.87%, and are now trading at a price of $96.40. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS